Pasar al contenido principal

MECANISMOS MOLECULARES REGULADOS POR RAS-PI3K DURANTE LA INTERACCION ENTRE CELULAS TUMORALES Y ESTROMA EN CANCER DE PULMON

RTI2018-099161-A-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE SALAMANCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction

  • Soriano, Olga
  • Alcón-Pérez, Marta
  • Vicente-Manzanares, Miguel
  • Castellano, Esther
© 2021 by the authors., Ras and Rho proteins are GTP-regulated molecular switches that control multiple signaling pathways in eukaryotic cells. Ras was among the first identified oncogenes, and it appears mutated in many forms of human cancer. It mainly promotes proliferation and survival through the MAPK pathway and the PI3K/AKT pathways, respectively. However, the myriad proteins close to the plasma membrane that activate or inhibit Ras make it a major regulator of many apparently unrelated pathways. On the other hand, Rho is weakly oncogenic by itself, but it critically regulates microfilament dynamics; that is, actin polymerization, disassembly and contraction. Polymerization is driven mainly by the Arp2/3 complex and formins, whereas contraction depends on myosin mini-filament assembly and activity. These two pathways intersect at numerous points: from Ras-dependent triggering of Rho activators, some of which act through PI3K, to mechanical feedback driven by actomyosin action. Here, we describe the main points of connection between the Ras and Rho pathways as they coordinately drive oncogenic transformation. We emphasize the biochemical crosstalk that drives actomyosin contraction driven by Ras in a Rho-dependent manner. We also describe possible routes of mechanical feedback through which myosin II activation may control Ras/Rho activation., This work was funded by the Spanish Ministry of Science and Innovation (SAF2017- 87408 and RTI2018-099161-A-I00), AECC Seed award (2018–IDEAS18018VICE) and ECRIN-M3 from AECC/AIRC/CRUK. IBMCC is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Ministry of Education of the Castilla–León Government (CLC–2017–01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The importance of being PI3K in the RAS signaling network

  • Cuesta, Cristina
  • Arévalo-Alameda, Cristina
  • Castellano, Esther
© 2021 by the authors, Ras proteins are essential mediators of a multitude of cellular processes, and its deregulation is frequently associated with cancer appearance, progression, and metastasis. Ras-driven cancers are usually aggressive and difficult to treat. Although the recent Food and Drug Administration (FDA) approval of the first Ras G12C inhibitor is an important milestone, only a small percentage of patients will benefit from it. A better understanding of the context in which Ras operates in different tumor types and the outcomes mediated by each effector pathway may help to identify additional strategies and targets to treat Ras-driven tumors. Evidence emerging in recent years suggests that both oncogenic Ras signaling in tumor cells and non-oncogenic Ras signaling in stromal cells play an essential role in cancer. PI3K is one of the main Ras effectors, regulating important cellular processes such as cell viability or resistance to therapy or angiogenesis upon oncogenic Ras activation. In this review, we will summarize recent advances in the understanding of Ras-dependent activation of PI3K both in physiological conditions and cancer, with a focus on how this signaling pathway contributes to the formation of a tumor stroma that promotes tumor cell proliferation, migration, and spread., This work was funded by the Spanish Ministry of Science and Innovation (RTI2018-099161-A-I00), and by Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Ministry of Education of the Castilla–León Government (CLC–2017–01).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma

  • Baltanás, Fernando C.
  • García-Navas, Rósula
  • Rodríguez-Ramos, Pablo
  • Calzada, Nuria
  • Cuesta, Cristina
  • Borrajo, Javier
  • Fuentes-Mateos, Rocío
  • Olarte-San Juan, Andrea
  • Vidaña-Bedera, Nerea
  • Castellano, Esther
  • Santos de Dios, Eugenio
The impact of genetic ablation of SOS1 or SOS2 is evaluated in a murine model of KRASG12D-driven lung adenocarcinoma (LUAD). SOS2 ablation shows some protection during early stages but only SOS1 ablation causes significant, specific long term increase of survival/lifespan of the KRASG12D mice associated to markedly reduced tumor burden and reduced populations of cancer-associated fibroblasts, macrophages and T-lymphocytes in the lung tumor microenvironment (TME). SOS1 ablation also causes specific shrinkage and regression of LUAD tumoral masses and components of the TME in pre-established KRASG12D LUAD tumors. The critical requirement of SOS1 for KRASG12D-driven LUAD is further confirmed by means of intravenous tail injection of KRASG12D tumor cells into SOS1KO/KRASWT mice, or of SOS1-less, KRASG12D tumor cells into wildtype mice. In silico analyses of human lung cancer databases support also the dominant role of SOS1 regarding tumor development and survival in LUAD patients. Our data indicate that SOS1 is critically required for development of KRASG12D-driven LUAD and confirm the validity of this RAS-GEF activator as an actionable therapeutic target in KRAS mutant LUAD., Work supported by grants ISCIII-MCUI (FIS PI19/00934), JCyL (SA264P18-UIC 076), Areces Foundation (CIVP19A5942), and ISCIII-CIBERONC (group CB16/12/00352) to E.S.; Solorzano-Barruso Foundation (FS/32-2020) and Eugenio Rodriguez Pascual Foundation to F.C.B.; MCI (RTI2018-099161-A-I00) to E.C. This research was co-financed by FEDER funds. These CIC groups are supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of Castilla y León autonomous government (CLC-2017-01) and AECC Excellence program Stop Ras Cancers (EPAEC222641CICS).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD

  • Baltanás, Fernando C.
  • Kramer Drauberg, Maximilian
  • García-Navas, Rósula
  • Patrucco, Enrico
  • Petrini, Ettore
  • Arnhof, Heribert
  • Olarte-San Juan, Andrea
  • Rodríguez-Ramos, Pablo
  • Borrajo, Javier
  • Calzada, Nuria
  • Castellano, Esther
  • Mair, Barbara
  • Kostyrko, Kaja
  • Hofmann, Marco H.
  • Ambrogio, Chiara
  • Santos de Dios, Eugenio
We evaluated the in vivo therapeutic efficacy and tolerability of BI-3406-mediated pharmacological inhibition of SOS1 in comparison to genetic ablation of this universal Ras-GEF in various KRAS-dependent experimental tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2KO mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. Allograft assays using different KRASmut cell lines showed that treatment with BI-3406 impaired RAS activation and RAS downstream signaling and decreased tumor burden and disease progression as a result of both tumor-intrinsic and -extrinsic therapeutic effects of the drug. Consistent with prior genetic evidence and the KRASmut allografts assays in immunocompromised mice, our analyses using an in vivo model of KRASG12D-driven lung adenocarcinoma (LUAD) in immunocompetent mice showed that single, systemic BI-3406 treatment impaired tumor growth and downmodulated protumorigenic components of the tumor microenvironment comparably to SOS1 genetic ablation or to treatment with the specific KRASG12D inhibitor MRTX1133. Furthermore, markedly stronger, synergistic antitumor effects were observed upon concomitant treatment with BI-3406 and MRTX1133 in the same in vivo LUAD mouse model. Our data confirm SOS1 as an actionable therapy target in RAS-dependent cancers and suggest that BI-3406 treatment may yield clinical benefit both as monotherapy or as a potential combination partner for multiple RAS-targeting strategies., Instituto de Salud Carlos III-Ministerio de Ciencia e Innovación grant FIS PI19/00934 (E.S.) Junta de Castilla y León grant SA264P18-UIC 076 (E.S.) Fundación Ramón Areces grant CIVP19A5942 (E.S.) Instituto de Salud Carlos III -CIBERONC grant CB16/12/00352 (E.S.) Asociación Española Contra el Cancer Excellence program STOP RAS CANCERS grant EPAEC222641CICS (E.S.) MICIU/AEI/10.13039/501100011033/ grant PID2022-136409OB-I00 (F.C.B.) MICIU/AEI/10.13039/501100011033/ and European Union NextGenerationEU/PRTR grant CNS2022-135292 (F.C.B.) Fundación Solorzano-Barruso grant FS/32-2020 (F.C.B.) Fundación Eugenio Rodríguez Pascual (F.C.B.) Asociación Inés de Pablo Llorens-Grupo GETTHI (F.C.B.) Ministerio de Ciencia e Innovación grant RTI2018-099161-A-I00 (E.C.) The Giovanni Armenise–Harvard Foundation (C.A.) The European Research Council under the European Union’s Horizon 2020 research and innovation programme grant 101001288 (C.A.) MIUR FARE grant R207ENY9KZ (C.A.) AIRC under IG 2021 - ID. 25737 (C.A.) This research was cofinanced by FEDER funds. These CIC groups are supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of Castilla y León autonomous government (CLC-2017-01). M.K.-D. was supported by Fondazione Umberto Veronesi. C.A. is supported by the Zanon di Valgiurata family through Justus s.s. The research project was selected and funded for 2 y by Boehringer Ingelheim in a Molecule for Collaboration (M4C) call submitted to the opn.me platform (www.opnme.com) We thank Astrid Jeschko for her contribution performing the Pharmacokinetic studies, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS-p110α signalling in macrophages is required for effective inflammatory response and resolution of inflammation

  • Rosell, Alejandro
  • Krygowska, Agata A.
  • Alcón Pérez, Marta
  • Cuesta, Cristina
  • Voisin, Mathieu-Benoit
  • Paz, Juan de
  • Sanz-Fraile, Héctor
  • Rajeeve, Vinothini
  • Berral-González, Alberto
  • Carreras-González, Ana
  • Swinyard, Ottilie
  • Gabandé-Rodriguez, Enrique
  • Downward, Julian
  • Alcaraz, Jordi
  • Anguita, Juan
  • García-Macías, Carmen
  • De Las Rivas, Javier
  • Cutillas, Pedro
  • Castellano, Esther
Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS-p110α signalling pathway, known for its involvement in various biological processes and tumorigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation. With emerging potential to activate p110α using small molecules, targeting the RAS-p110α pathway could be a promising approach for treating chronic inflammation. This therapeutic prospect holds significant promise for easing inflammatory disorders and improving the quality of life for affected patients., Consejo Superior de Investigaciones Científicas JAEICU-21-IBMCC-6 Alejandro Rosell Junta de Castilla y León CSI185-20 Marta Alcón Pérez Marie Curie PF7 MCA-ITN317445 Agata Adelajda Krygowska Ministerio de Ciencia e Innovación RTI2018-099161-A-I00 Alejandro Rosell Cristina Cuesta Juan de Paz Esther Castellano Sanchez Asociación Española Contra el Cáncer EPAEC222641CICS Juan de Paz Junta de Castilla y León CLC-2017-01 Esther Castellano Sanchez CRUK Barts Centre Development Fund Esther Castellano Sanchez, Peer reviewed